186 related articles for article (PubMed ID: 34646386)
21. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
[TBL] [Abstract][Full Text] [Related]
22. Quantitative contrast-enhanced ultrasound evaluation of pathological complete response in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy.
Wan CF; Liu XS; Wang L; Zhang J; Lu JS; Li FH
Eur J Radiol; 2018 Jun; 103():118-123. PubMed ID: 29803376
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
Sharma P; Stecklein SR; Yoder R; Staley JM; Schwensen K; O'Dea A; Nye L; Satelli D; Crane G; Madan R; O'Neil MF; Wagner J; Larson KE; Balanoff C; Kilgore L; Phadnis MA; Godwin AK; Salgado R; Khan QJ; O'Shaughnessy J
JAMA Oncol; 2024 Feb; 10(2):227-235. PubMed ID: 37991778
[TBL] [Abstract][Full Text] [Related]
24. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
Zhao Y; Schaafsma E; Cheng C
Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
[TBL] [Abstract][Full Text] [Related]
25. Using Flow Characteristics in Three-Dimensional Power Doppler Ultrasound Imaging to Predict Complete Responses in Patients Undergoing Neoadjuvant Chemotherapy.
Shia WC; Huang YL; Wu HK; Chen DR
J Ultrasound Med; 2017 May; 36(5):887-900. PubMed ID: 28109009
[TBL] [Abstract][Full Text] [Related]
26. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
27. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
[TBL] [Abstract][Full Text] [Related]
29. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Shinde AM; Zhai J; Yu KW; Frankel P; Yim JH; Luu T; Kruper L; Vito C; Shaw S; Vora NL; Kirschenbaum M; Somlo G
Breast; 2015 Feb; 24(1):18-23. PubMed ID: 25467313
[TBL] [Abstract][Full Text] [Related]
30. In vivo study of enhanced chemotherapy combined with ultrasound image-guided focused ultrasound (USgFUS) treatment for pancreatic cancer in a xenograft mouse model.
Park EJ; Ahn YD; Lee JY
Eur Radiol; 2018 Sep; 28(9):3710-3718. PubMed ID: 29600477
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
32. Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
Wang Y; Brodsky AS; Xiong J; Lopresti ML; Yang D; Resnick MB
Clin Breast Cancer; 2018 Jun; 18(3):e373-e379. PubMed ID: 28890185
[TBL] [Abstract][Full Text] [Related]
33. Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer.
Cao X; Xue J; Zhao B
Ultrasound Med Biol; 2012 Dec; 38(12):2065-71. PubMed ID: 23062366
[TBL] [Abstract][Full Text] [Related]
34. Contrast-enhanced ultrasonography and blue dye methods in detection of sentinel lymph nodes following neoadjuvant chemotherapy in initially node positive breast cancer.
Wu X; Tang L; Huang W; Huang S; Peng W; Hu D
Arch Gynecol Obstet; 2020 Sep; 302(3):685-692. PubMed ID: 32602000
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
[TBL] [Abstract][Full Text] [Related]
36. Role of low-mechanical index CEUS in the differentiation between low and high grade bladder carcinoma: a pilot study.
Drudi FM; Cantisani V; Liberatore M; Iori F; Erturk SM; Cristini C; Di Pierro G; D'Ambrosio U; Malpassini F; De Felice C; Di Leo N
Ultraschall Med; 2010 Dec; 31(6):589-95. PubMed ID: 20449795
[TBL] [Abstract][Full Text] [Related]
37. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Denkert C; von Minckwitz G; Brase JC; Sinn BV; Gade S; Kronenwett R; Pfitzner BM; Salat C; Loi S; Schmitt WD; Schem C; Fisch K; Darb-Esfahani S; Mehta K; Sotiriou C; Wienert S; Klare P; André F; Klauschen F; Blohmer JU; Krappmann K; Schmidt M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Untch M; Loibl S
J Clin Oncol; 2015 Mar; 33(9):983-91. PubMed ID: 25534375
[TBL] [Abstract][Full Text] [Related]
38. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
39. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
40. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
